The 12-month price targets, analyzed by analysts, offer insights with an average target of $37.89, a high estimate of $47.00, ...

Stocks Crushing the Market, 6 Climb to Fresh Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the top performers on ...

Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Travere Therapeutics, Inc. (TVTX) shares are trading higher on Wednesday after the company announced that it was informed by ...

Travere Therapeutics, Inc. is rated Buy with FILSPARI’s robust growth, FDA approval, and key milestones ahead. Click here to ...

Travere Therapeutics (NASDAQ:TVTX) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ...

4 analysts have expressed a variety of opinions on Travere Therapeutics (NASDAQ:TVTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent ...

Stifel raised the firm’s price target on Travere Therapeutics (TVTX) to $25 from $20 and keeps a Hold rating on the shares following the announcement that FDA no longer plans to hold an advisory ...

If approved, FILSPARI would be the first medication indicated for FSGS, a rare and serious kidney disorder driven by ...

Travere Therapeutics (TVTX) has witnessed significant developments, including the FDA's decision not to call an advisory committee meeting for the sNDA of FILSPARI®, while the drug is still under ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 20 new employees, ...